Please login to the form below

Not currently logged in
Email:
Password:

Bioniche appoints James Rae as chair

He previously led several Canadian biopharma firms as CEO

Bioniche has named James Rae, CEO of Viron Therapeutics, as chair of its board of directors.

He replaces Graeme McRae at the Canadian company, with McRae retaining his position as CEO and president.

"Mr Rae brings a wealth of sector experience to our board of directors," said McRae. "His knowledge and network will serve the company well as we work to complete important R&D projects and grow revenues."

Rae has a rich pedigree in the Canadian biopharma industry serving as CEO at several companies.

Prior to joining Viron in 2007, he was CEO of Cytochroma, chair and CEO of Resolution pharma, and chair and CEO of Vaxis Therapeutics.

Extending back even further, he also served as president and CEO of Cangene, where he was responsible for restructuring and orchestrating a takeover of the company.

He began his pharma career at Searle, where he spent 18 years, including several as CEO.

Bioniche also announced several changes to its senior management structure, with Cameron Groome, executive VP, corporate & strategic development; Jim Phillips, senior VP, industry relations; Dr Dragan Rogan, chief veterinary scientific officer and Dr Gary Weber, president, Bioniche Food Safety (US) all leaving the company.

Michael Rubin has joined Bioniche, however, as VP, business development.

1st August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Can Cinderella save us?
The impending threat of antibiotic resistance
Antibiotic Research UK is the BIA's charity of 2015, but what does it intend to do?...
UK life sciences minister George Freeman
Creating a 21st century life sciences ecosystem
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation...
Improving Corporate Memory as a Patient Safety Strategy
An article by Lorri Zipperer...